Literature DB >> 26224449

Comment on: "Healthy Decisions: Towards Uncertainty Tolerance in Healthcare Policy".

Afschin Gandjour1.   

Abstract

Mesh：

Year:  2015        PMID： 26224449     DOI： 10.1007/s40273-015-0317-4

Source DB:  PubMed          Journal:  Pharmacoeconomics        ISSN： 1170-7690            Impact factor:   4.981


× No keyword cloud information.
  13 in total

1.  Cost-effectiveness analysis with risk aversion.

Authors:  J G Zivin
Journal:  Health Econ       Date:  2001-09       Impact factor: 3.046

Review 2.  Taking account of future technology in cost effectiveness analysis.

Authors:  Joshua A Salomon; Milton C Weinstein; Sue J Goldie
Journal:  BMJ       Date:  2004-09-25

3.  Risk aversion and uncertainty in cost-effectiveness analysis: the expected-utility, moment-generating function approach.

Authors:  Elamin H Elbasha
Journal:  Health Econ       Date:  2005-05       Impact factor: 3.046

4.  Presenting Germany's drug pricing rule as a cost-per-QALY rule.

Authors:  Afschin Gandjour
Journal:  Health Care Manag Sci       Date:  2011-12-21

5.  Optimal allocation of resources over health care programmes: dealing with decreasing marginal utility and uncertainty.

Authors:  Maiwenn J Al; Talitha L Feenstra; Ben A van Hout
Journal:  Health Econ       Date:  2005-07       Impact factor: 3.046

6.  Germany's decision rule for setting ceiling prices of drugs: a comparative analysis with other decision rules.

Authors:  Afschin Gandjour
Journal:  Appl Health Econ Health Policy       Date:  2011-03-01       Impact factor: 2.561

7.  The German method for setting ceiling prices for drugs: in some cases less data are required.

Authors:  Afschin Gandjour; Amiram Gafni
Journal:  Expert Rev Pharmacoecon Outcomes Res       Date:  2011-08       Impact factor: 2.217

8.  Healthy decisions: towards uncertainty tolerance in healthcare policy.

Authors:  Janneke P C Grutters; Marjolein B A van Asselt; Kalipso Chalkidou; Manuela A Joore
Journal:  Pharmacoeconomics       Date:  2015-01       Impact factor: 4.981

9.  Comment on: "Are current cost-effectiveness thresholds for low- and middle-income countries useful? Examples from the world of vaccines".

Authors:  Afschin Gandjour
Journal:  Pharmacoeconomics       Date:  2014-12       Impact factor: 4.981

10.  Prioritizing comparative effectiveness research: are drug and implementation trials equally worth funding?

Authors:  Afschin Gandjour
Journal:  Pharmacoeconomics       Date:  2011-07       Impact factor: 4.558
View more
  1 in total

1.  Cost-effectiveness of sofosbuvir in hepatitis C genotype 1 infection in Germany: A reanalysis of published results.

Authors:  Afschin Gandjour
Journal:  PLoS One       Date:  2020-10-02       Impact factor: 3.240
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.